Organovo Holdings, Inc. – NASDAQ:ONVO
Organovo Holdings stock price today
$2.04
+1.67
+455.86%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
Organovo Holdings stock price monthly change
-45.87%
month
Organovo Holdings stock price quarterly change
-45.87%
quarter
Organovo Holdings stock price yearly change
-68.09%
year
Organovo Holdings key metrics
Market Cap | 5.19M |
Enterprise value | N/A |
P/E | -1.63 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 12.32 |
Price/Book | 0.87 |
PEG ratio | -0.03 |
EPS | -1.61 |
Revenue | N/A |
EBITDA | -14.96M |
Income | -14.67M |
Revenue Q/Q | -82.09% |
Revenue Y/Y | -70.54% |
Profit margin | -742.61% |
Oper. margin | -752.38% |
Gross margin | 0% |
EBIT margin | -752.38% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOrganovo Holdings stock price history
Organovo Holdings stock forecast
Organovo Holdings financial statements
| Jun 2023 | 75K | -4.02M | -5370.67% |
|---|---|---|---|
| Sep 2023 | 0 | -3.99M | |
| Dec 2023 | 5K | -3.60M | -72080% |
| Mar 2024 | 29K | -3.04M | -10500% |
| Mar 2024 | 29K | -3.04M | -10500% |
|---|---|---|---|
| Oct 2025 | 35K | -3.32M | -9501.85% |
| Dec 2025 | 35K | -3.12M | -8925.99% |
| Mar 2026 | 31K | -2.62M | -8452.29% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 14756000 | 2.98M | 20.2% |
|---|---|---|---|
| Sep 2023 | 11161000 | 2.70M | 24.24% |
| Dec 2023 | 8881000 | 2.69M | 30.39% |
| Mar 2024 | 6349000 | 2.74M | 43.28% |
| Jun 2023 | -5.31M | 764K | 0 |
|---|---|---|---|
| Sep 2023 | -3.14M | 12K | 0 |
| Dec 2023 | -3.52M | 27K | 1.17M |
| Mar 2024 | -2.67M | 13K | 264K |
Organovo Holdings alternative data
| Aug 2023 | 15 |
|---|---|
| Sep 2023 | 23 |
| Oct 2023 | 23 |
| Nov 2023 | 23 |
| Dec 2023 | 23 |
| Jan 2024 | 23 |
| Feb 2024 | 23 |
| Mar 2024 | 18 |
| Apr 2024 | 18 |
| May 2024 | 18 |
| Jun 2024 | 18 |
| Jul 2024 | 12 |
Organovo Holdings other data
3.38%
-18.13%
of ONVO is owned by hedge funds
20
-11
294.89K
-1.57M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Nov 2023 | 0 | 19607 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | GOBEL DAVID director | Common Stock | 19,607 | $1.62 | $31,744 | ||
Purchase | COHEN DOUGLAS JAY director | Common Stock | 9,750 | $6.72 | $65,540 | ||
Sale | HUGHES STEVEN GEORGE officer: Chief Medical Officer | Common Stock | 22,230 | N/A | N/A | ||
Sale | PRESNELL SHARON COLLINS officer: Chief Scientific Officer | Common Stock | 40,000 | N/A | N/A | ||
Purchase | MURPHY KEITH director, officer.. | Common Stock | 200,500 | N/A | N/A | ||
Purchase | MURPHY KEITH director, officer.. | Common Stock | 135,000 | N/A | N/A | ||
Sale | MURPHY KEITH director, officer.. | Common Stock | 25,000 | N/A | N/A | ||
Option | MURPHY KEITH director, officer.. | Warrant | 30,000 | N/A | N/A | ||
Option | MURPHY KEITH director, officer.. | Common Stock | 30,000 | N/A | N/A | ||
Sale | MURPHY KEITH director, officer.. | Common Stock | 20,100 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q4 2019 23 May 2019 | Q4 2019 Earnings Call Transcript |
| Q3 2019 8 Feb 2019 | Q3 2019 Earnings Call Transcript |
| Q2 2019 9 Nov 2018 | Q2 2019 Earnings Call Transcript |
| Q1 2019 9 Aug 2018 | Q1 2019 Earnings Call Transcript |
-
What's the price of Organovo Holdings stock today?
One share of Organovo Holdings stock can currently be purchased for approximately $2.04.
-
When is Organovo Holdings's next earnings date?
Unfortunately, Organovo Holdings's (ONVO) next earnings date is currently unknown.
-
Does Organovo Holdings pay dividends?
No, Organovo Holdings does not pay dividends.
-
How much money does Organovo Holdings make?
Organovo Holdings has a market capitalization of 5.19M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 92.73% to 109K US dollars.
-
What is Organovo Holdings's stock symbol?
Organovo Holdings, Inc. is traded on the NASDAQ under the ticker symbol "ONVO".
-
What is Organovo Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Organovo Holdings?
Shares of Organovo Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Organovo Holdings's key executives?
Organovo Holdings's management team includes the following people:
- Mr. Keith E. Murphy Executive Chairman & Principal Executive Officer(age: 53, pay: $397,180)
- Mr. Thomas Einar Jurgensen J.D., MS Gen. Counsel & Corporation Sec.(age: 68, pay: $264,860)
- Dr. Jeffrey N. Miner Chief Scientific Officer(age: 63, pay: $221,090)
-
How many employees does Organovo Holdings have?
As Jul 2024, Organovo Holdings employs 12 workers, which is 33% less then previous month and 33% less then previous quarter.
-
When Organovo Holdings went public?
Organovo Holdings, Inc. is publicly traded company for more then 13 years since IPO on 14 Feb 2012.
-
What is Organovo Holdings's official website?
The official website for Organovo Holdings is organovo.com.
-
Where are Organovo Holdings's headquarters?
Organovo Holdings is headquartered at 11555 Sorrento Valley Road, Solana Beach, CA.
-
How can i contact Organovo Holdings?
Organovo Holdings's mailing address is 11555 Sorrento Valley Road, Solana Beach, CA and company can be reached via phone at 858 224 1000.
Organovo Holdings company profile:
Organovo Holdings, Inc.
organovo.comExchange:
NASDAQ
Full time employees:
12
Industry:
Biotechnology
Sector:
Healthcare
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
11555 Sorrento Valley Road
Solana Beach, CA 92121
Solana Beach, CA 92121
CIK: 0001497253
ISIN: US68620A2033
CUSIP: 68620A203
